证券代码：688180 证券简称：君实生物 公告编号：临 2026-003 上海君实生物医药科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现营业收入 250,000.00 万元左 右，与上年同期相比增长 55,168.27 万元左右，同比增长 28.32%左右。 2、预计 2025 年年度研发费用为 135,300.00 万元左右，与上年同期相比增长 7,772.99 万元左右，同比增长 6.10%左右。 3、预计 2025 年年度实现归属于母公司所有者的净利润-87,300.00 万元左右， 与上年同期相比亏损减少 40,792.64 万元左右，同比亏损减少 31.85%左右。预计 2025年年度扣除股份支付影响后实现归属于母公司所有者的净利润-79,900.00万 元左右，与上年同期相比亏损减少 4 ...

Core Insights - The 2025 Innovation Summit, hosted by Economic Observer, focused on themes such as artificial intelligence, digital transformation, robotics, and biomedicine, gathering entrepreneurs, scholars, and industry leaders to share cutting-edge developments and innovative practices [1] - China is entering a new phase of global industrial competition characterized by "innovation racing and cluster breakthroughs," with "new quality productivity" reshaping traditional growth paths through advancements in AI, semiconductor technology, aerospace economy, robotics, and biomedicine [1] - The summit highlighted 20 leading companies recognized for their technological advancements and contributions to industry ecosystems, serving as benchmarks for innovation and value realization during the 14th Five-Year Plan period [1] Industry Highlights - The development of new quality productivity is transitioning from single-point technological breakthroughs to deep integration within industrial scenarios, emphasizing the need for solid innovative practices and implementable development paradigms [1] - The summit introduced the "Qianxing List" featuring outstanding innovative enterprises and benchmark practices, showcasing the industry's core strengths and innovative capabilities [1] Company Case Studies - Bai Li Tian Heng's transformation practice was highlighted as a significant case [3] - The Iza-Bren dual-antibody ADC research project aims to fill treatment gaps for multiple tumor types, leading global breakthroughs in innovative oncology drugs [4] - Huawei's business attribute-based monitoring solution for the securities industry was presented as a key innovation [5] - The Wangdong health management solution case from Wenzhou People's Hospital was showcased by Huawei [6] - Kingsoft Office's WPS 365 smart education platform was recognized for empowering digital upgrades in higher education [7] - JD Technology's AI innovation practices in government services were also featured [7] - The establishment of a commercial production line EBR system by iFlytek aims to empower high-quality development in the biomedicine industry through digital upgrades [8] - iFlytek's Starfire large model demonstrates full-scenario penetration and value creation [9] - Kuaishou Technology's AI-assisted interactive comics address pain points in AI companionship, creating a new upgraded paradigm for comic experiences [10] - Ant Group's technological breakthroughs and commercialization practices in AI were highlighted [11] - Qianshi Technology's Lingguang App leads a new paradigm for multimodal AI assistants [12] - Schneider Electric's WYLON® large model integrated machine showcases innovative practices [13] - Yiling Pharmaceutical's predictive maintenance system based on multimodal large models demonstrates technological breakthroughs and scalable applications [14]

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 831.03%, Zhejiang Shibao (01057) at 339.32%, and Sinopec Oilfield Service (01033) at 323.71% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -14.62%, China Merchants Bank (03968) at -3.22%, and Hengrui Medicine (01276) at 1.77% [1][2] - Sinopec Oilfield Service (01033), Andeli Juice (02218), and Shandong Molong (00568) have the highest deviation values at 53.41%, 21.68%, and 19.01% respectively [1][2] Group 2 - The companies with the lowest deviation values include Zhejiang Shibao (01057) at -58.91%, Yangtze Optical Fibre and Cable (06869) at -49.00%, and Fudan Zhangjiang (01349) at -24.81% [1][2][4] - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) and Beijing Electromechanical (00187) with premium rates of 258.91% and 257.99% respectively [2] - The bottom ten AH stocks by premium rate include Weichai Power (02338) and Midea Group (00300) with premium rates of 6.84% and 8.51% respectively [2]

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Nanhua Futures (02691) saw the largest increase in holdings, up by 4.45% to a total of 10.44% [2]. - Junshi Biosciences (01877) experienced a 2.39% increase, bringing its total holding to 55.84% [2]. - Lion Group (02562) had a 2.21% increase, resulting in a holding of 53.31% [2]. - Other notable increases include Haotian International Investment (01341) at +1.61% (67.02%) and Junda Co., Ltd. (02865) at +1.43% (59.68%) [2]. Group 2: Companies with Decreased Holdings - Yihua Tong (02402) reported the largest decrease, down by 2.06% to 28.06% [2]. - Shandong Molong (00568) saw a reduction of 1.99%, with a current holding of 58.26% [2]. - Jihong Co., Ltd. (02603) decreased by 1.27%, now holding 57.37% [2]. - Other significant decreases include China Merchants Hengsheng Technology (03423) at -0.85% (3.15%) and CIFI Holdings Group (00884) at -0.82% (9.03%) [2]. Group 3: Five-Day Changes in Holdings - Junda Co., Ltd. (02865) had the highest five-day increase at +12.13%, reaching 59.68% [3]. - Nanhua Futures (02691) increased by 9.08% to 10.44% [3]. - Other notable increases include Baidu Biotechnology-B (02315) at +3.13% (22.65%) and Junshi Biosciences (01877) at +2.77% (55.84%) [3]. Group 4: Twenty-Day Changes in Holdings - Junda Co., Ltd. (02865) also led the twenty-day increase with +27.85%, holding 59.68% [4]. - Baidu Biotechnology-B (02315) increased by +14.85% to 22.65% [4]. - Other significant increases include Zhongwei New Materials (02579) at +11.72% (16.27%) and Youjia Innovation (02431) at +8.62% (14.46%) [4].

一款已在国内上市的用于新冠治疗的口服药物VV116(民得维)，有望成为应对致死率高达70%尼帕病毒 的武器。 近期，在国际期刊《Emerging Microbes&Infections》(《新兴微生物与感染》)上，中国科学院武汉病毒 研究所等机构的研究团队发表了一项重要成果，证实已上市的VV116对尼帕病毒具有显著的抗病毒活 性。 据媒体报道，尼帕病毒被世界卫生组织(WHO)列为最高优先级的区域性威胁，其宿主范围广、致死率 高，且目前全球尚无获批的特效药物或疫苗。最新动物实验研究显示，口服VV116能将受尼帕病毒感染 金黄地鼠的存活率提升至66.7%，并显著降低其关键器官中的病毒载量，这为应对潜在的尼帕病毒疫情 提供了一个"现成的药物选择"。 然而，对于这一重大发现，VV116的国内合作开发方——君实生物与旺山旺水进行了相关回应，但回应 内容现"温差"。 更具说服力的数据来自对金黄地鼠进行的试验。 在金黄地鼠的致死剂量感染模型中，研究团队通过口服给药的方式对尼帕病毒感染动物进行治疗。 日前，君实生物工作人员向《每日经济新闻》记者表示，公司并未进行类似的研究，拓展新适应证需临 床数据支持。 而旺山旺水方面则向《 ...

君实生物2022年度向特定对象发行A股股票募集资金情况为，根据中国证监会出具的《关于同意上 海君实生物医药科技股份有限公司向特定对象发行股票注册的批复》(证监许可[2022]2616号)，公司获 准向特定对象发行人民币普通股7,000.00万股，每股发行价格为人民币53.95元，募集资金总额为人民币 3,776,500,000.00元；扣除各项发行费用合计人民币31,697,205.06元(不含增值税)后，实际募集资金净额 为人民币3,744,802,794.94元。实际到账金额为人民币3,759,350,000.00元，包括尚未支付的其他发行费用 人民币14,547,205.06元。上述资金已于2022年11月23日到位，容诚会计师事务所(特殊普通合伙)对公司 本次向特定对象发行股票的资金到位情况进行了审验，并于2022年11月24日出具了容诚验字 [2022]230Z0337号《验资报告》。募集资金到账后，已全部存放于公司开设的募集资金专项账户内。 中国经济网北京1月29日讯 君实生物(688180.SH)今日收报36.82元，跌幅6.02%。该股目前处于破发 状态。 君实生物于2020年7月15日在上交 ...

Group 1: Nipah Virus Outbreak in India - The recent Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers [1] - Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infection and fatal encephalitis [1] Group 2: Company Responses and Developments - Wanfu Bio has launched various Nipah virus nucleic acid test kits, adaptable to their U-CardDx 200 platform and other PCR systems, to meet screening and detection needs [1] - Shengxiang Bio has developed a Nipah virus nucleic acid test kit based on fluorescence PCR technology, with CE certification and a focus on rapid response to public health events [2] - Capbio emphasizes the importance of their Nipah virus test kit for global quarantine and disease control efforts, highlighting its precise detection capabilities [2] - Zhijiang Bio's Nipah virus PCR test kit offers higher sensitivity and accuracy, aiming to shorten the diagnosis window [2] - Da'an Gene has created a Nipah virus nucleic acid test kit with a sensitivity of 200 copies/mL, reducing the risk of false negatives [2] Group 3: Research on Treatment - Research teams from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica have confirmed that the oral nucleoside drug VV116 shows significant antiviral activity against Nipah virus [3] Group 4: Clarifications from Companies - Hualan Biological has clarified that it does not have any products related to Nipah virus, focusing instead on human vaccine manufacturing for influenza [4] - Companies such as Jindike, Yirui Bio, and Renhe Pharmaceutical have publicly stated they do not have any Nipah virus-related products [4]

Core Viewpoint - The report highlights the AH premium rates of various stocks, indicating significant disparities between H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums [1][2]. Group 1: Top AH Premium Rates - Northeast Electric (00042) leads with an AH premium rate of 847.37%, followed by Zhejiang Shibao (01057) at 349.31% and Beijing Jingcheng Machinery Electric (00187) at 279.42% [1][2]. - The lowest AH premium rates are recorded for Contemporary Amperex Technology (03750) at -14.34%, China Merchants Bank (03968) at -4.99%, and Heng Rui Medicine (01276) at -1.15% [1][2]. Group 2: Top AH Deviation Values - Junshi Biosciences (01877) has the highest deviation value at 22.43%, followed closely by Beijing Jingcheng Machinery Electric (00187) at 22.18% and CanSino Biologics (06185) at 21.90% [1][3]. - The lowest deviation values are observed in Changfei Optical Fiber (06869) at -50.58%, Zhejiang Shibao (01057) at -45.38%, and Nanhua Futures (02691) at -27.12% [1][4]. Group 3: Detailed AH Premium and Deviation Rankings - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) with a premium of 271.30% and Sinopec Oilfield Service (01033) at 248.51% [2]. - The bottom ten AH stocks by premium rate include WuXi AppTec (02359) with a slight premium of 0.42% and Midea Group (00300) at 6.75% [2]. - The top ten stocks by deviation also feature companies like Goldwind (02208) at 19.35% and Andeli Juice (02218) at 19.04% [3].

Group 1: Nipah Virus Outbreak - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases, with nearly 100 individuals under observation [1] - Neighboring countries like Thailand and Nepal have increased health screening measures for travelers from India [1] - The World Health Organization (WHO) states that Nipah virus is zoonotic and can be transmitted from infected animals to humans, with symptoms including acute respiratory infections and fatal encephalitis [1] Group 2: VV116 Drug Development - VV116 is an oral nucleoside drug with broad-spectrum antiviral potential, developed by Wangshan Wangshui and Junshi Biosciences [2][4] - Recent research published in the journal Emerging Microbes & Infections confirms that VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [1][6] - The drug has previously been approved for COVID-19 treatment in China and Uzbekistan, and its commercialization has significantly contributed to the company's revenue [4] Group 3: Market Response and Stock Performance - Following the announcement of VV116's potential against Nipah virus, Wangshan Wangshui's stock rose by 10.9%, reaching a new high since its listing in November 2025 [2] - Other companies in the IVD sector, such as Kaipu Bio and Da'an Gene, have also seen stock price increases due to their development of Nipah virus detection kits [9] - The market sentiment towards high-pathogenic virus detection has intensified, with multiple diagnostic companies reporting stock price gains [9] Group 4: Clinical and Regulatory Developments - VV116 has shown potential in animal models to improve survival rates against Nipah virus infections, indicating its possible use as a preventive treatment for high-risk populations [6] - The Chinese government has included Nipah virus in its health quarantine regulations, emphasizing the importance of rapid laboratory diagnostics for outbreak control [8] - Several companies have developed and announced their Nipah virus detection technologies, enhancing the diagnostic capabilities in response to the outbreak [8][9]

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]